ArticleImmunity, inflammation and disease2022
Epidemiology of rhinovirus under the COVID-19 pandemic in Guangzhou, China, 2020.
Article in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Prevalence of respiratory viruses in children with respiratory tract infections during the COVID-19 pandemic era: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Molecular Types of Rhinovirus Among Cases of Acute Respiratory Infections in a University Hospital.Journal of medical virology · 2026Article
- rhinotypeR enables reproducible rhinovirus genotype assignment from VP4/2 sequences.Scientific reports · 2026Article
- Pathogen profiles and co-detection characteristics of acute respiratory infections based on active surveillance in a large district of southern China.Frontiers in public health · 2026Article
- Surveillance of respiratory viruses in severe acute respiratory infections in Southern Brazil, 2023-2024.BMC infectious diseases · 2025Article
- Seasonal dynamics and genetic diversity of human rhinoviruses in patients with acute respiratory infection in Bangkok in 2024.Archives of virology · 2025Article
- Observational
- Rhinovirus dynamics across different social structures.Npj viruses · 2023Article
- Epidemiology of rhinovirus under the COVID-19 pandemic in Guangzhou, China, 2020.Immunity, inflammation and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyze the epidemic characteristics of the human rhinovirus (HRV) outbreaks in Guangzhou, China, in 2020.
methodsDescriptive epidemiological methods were used to analyze the HRV-related outbreaks in Guangzhou, 2020.
resultsSeventeen outbreaks were reported in 2020 during the coronavirus disease 2019 (COVID-19) pandemic in Guangzhou, a total of 465 patients (290 males and 175 females) were enrolled, with a median age of 10. A total of 223 (47.96%) had been tested for HRV, 89 (39.91%) of which were positive; 344/465 (73.98%) had a fever, 138/465 (29.68%) had a runny nose, 139/465 (29.89%) had a sore throat, 86/465 (18.49%) had a cough, 41/465 (8.82%) had a headache, and 37/465 (7.96%) had a sneeze. Patients at age of 13-15 had the highest rate of sore throat and runny nose, patients aged 11-12 had the highest rate of sneezing, and patients at age of 12-14 had the highest rate of positive rate. Patients tested positive had a higher rate of fever (χ
conclusionThe HRV was restored during the fighting of the COVID-19 pandemic. The conventional COVID-19 control measures were not effective enough in preventing rhinovirus. More appropriate control measures should be used to control HRV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.